

# aap Implantate AG

Revised forecasts

LOQTEQ set for launch in the US in Q3

aap should reach its FY15 guidance after a solid Q1 and distribution deals enabling a US launch of LOQTEQ in Q3. However, we trim our CAGR 2014-18e revenue from 15% to 12% and our valuation from €3.17 to €3.05 per share. An eventual sale of Biomaterials may prompt a re-rating of the fast-growing trauma business.

Year end	Revenue (€m)	PBT* (€m)	EPS* (c)	DPS (c)	P/E (x)	Yield (%)
12/14	30.6	0.7	0.9	0.0	N/A	N/A
12/15e	34.2	1.1	2.3	0.0	N/A	N/A
12/16e	38.1	3.0	8.0	0.0	30.0	N/A
12/17e	43.2	6.3	17.9	0.0	13.4	N/A

Note: \*PBT and EPS are normalised, excluding intangible amortisation, exceptional items and share-based payments. 2013 and 2014 sales are for continuing operations only.

## On track to meet FY15e financial guidance

aap's Q1 trading was solid: group revenues rose 16% to €7.1m, of which Biomaterials' portion grew 23% to €4.4m and LOQTEQ soared by 45% to €1.7m. This was balanced by LOQTEQ's cannibalisation of other Trauma revenues, which declined 27% to €0.8m. aap expects LOQTEQ to grow by c 25% in FY15, helped by the planned launch in the US and possibly Brazil in H2. Also, aap is working to raise delivery capacity and reduce production costs. This should enable it to meet its financial guidance of €33-35m revenue and €2.5-3.5m EBITDA in FY15e and to grow revenues and profits considerably in FY16e.

## LOQTEQ's US market entry in the offing

aap has signed US distributor agreements, paving the way for launch of LOQTEQ in six states in Q3. In addition to these non-stocking distributors, it plans to engage stock-carrying intermediaries, which we believe will yield a more immediate sales contribution. Further, aap's position has been reinforced in recent months by intellectual property awards in Europe for LOQTEQ, the antimicrobial silver and the resorbable magnesium technologies, mirroring previous awards in the US.

## Biomaterials sale could boost growth

While the sales process stalled in Q1, aap still aims to sell the Biomaterials division. We estimate a sale could raise €35-40m (8-9x EBITDA). The resulting cash could be deployed to bolster Trauma (acquisitions and organic growth) and to repurchase shares for up to €3m pa (10% of subscribed capital). Also, being focused on IP-protected trauma products may make aap a more attractive acquisition target.

## Valuation: Attractive upside remains despite EPS cut

We have trimmed our sales estimates, due to a more paced roll-out of LOQTEQ and its stronger cannibalisation of other Trauma sales, and our profit forecasts as a result of expected higher depreciation charges in FY15e and FY16e. Based on a DCF, we reduce our valuation from €97m to €94m or €3.05 per share. An eventual sale of Biomaterials may crystallise €3.42 per share.

Healthcare equipment &amp; services

30 June 2015

**Price** €2.40

**Market cap** €74m

Net cash (€m) at end FY14e 7.7

Shares in issue 30.7m

Free float 34%

Code AAQ

Primary exchange Xetra

Secondary exchange N/A

### Share price performance



### Business description

aap Implantate is a German medtech company, focused on developing, manufacturing and selling products for bone fractures. These include the recently launched LOQTEQ trauma plating system, in addition to bone cements.

### Next events

H115 results 14 August 2015

Q315 results 13 November 2015

### Analysts

Hans Bostrom +44 (0)20 3681 2522

Dr Philippa Gardner +44 (0)20 3681 2521

[healthcare@edisongroup.com](mailto:healthcare@edisongroup.com)
[Edison profile page](#)

## Financial forecast changes

Our FY15 and FY16 revenue forecasts have been trimmed by 3% and 6%, respectively, reflecting a more paced international roll-out of LOQTEQ and its higher degree of cannibalisation on other Trauma product sales than previously forecast. Our new EBITDA forecasts reflect the lower revenue forecasts and fixed overhead costs. Additionally, we have raised our forecasts for depreciation and amortisation to reflect upgraded capex forecasts, which is the main additional factor affecting our new net income forecasts.

Exhibit 1: Financial forecast changes						
€m	2015e			2016e		
	Old	New	Change	Old	New	Change
Revenue	35.2	34.2	-3%	40.5	38.1	-6%
Gross profit	22.5	21.7	-4%	25.9	24.3	-6%
EBITDA	3.4	3.0	-12%	6.3	5.0	-20%
Net income (normalised)	2.3	0.7	-70%	4.5	2.5	-45%

Source: Edison Investment Research

## Valuation

We value aap at €94m or €3.05 per share, based on DCF. The key assumptions in our DCF valuation are a 10% discount rate and a 2% long-term growth rate after a two-stage forecast period: 2015-19e and 2020-29e (with growth phased down from 10% to 2%). The downgrade from €3.17 reflects rolling forward the model (positive) and a more conservative view on Trauma revenues, owing largely to LOQTEQ cannibalising to a higher degree than expected other Trauma revenues. However, we have also tweaked our assumptions for capitalisation on R&D (lower), working capital (lower) and capex (higher) which, taken together, largely compensate for the EBIT shortfall.

For illustration, we estimate that a sale of the Biomaterials division could yield net sales proceeds of €35m after tax of €1.3-1.8m, which would be added to net cash of €7.7m at end 2014. This would yield a pro forma enterprise value of €31m (current EV €66m), leaving the remaining fast-growing Trauma business trading at 2.10x Trauma sales of €14.8m in 2015e (previously €17.5m) vs 3.13x for its global orthopaedic peers. Weighing both its superior growth but likely inferior profitability relative to its orthopaedic peers, we consider that aap without Biomaterials could be valued at 4.2x EV/Sales (€62m enterprise value), a premium to the broader orthopaedic peer group but in line with the smaller and more comparable Wright Medical and Tornier, which are soon to merge. On this multiple, the addition of €43m in cash gives a market cap of €105m and a valuation per share of €3.42. The downgrade from €3.8 per share of this illustrative valuation reflects the lowering of our FY15 Trauma revenue forecast.

Exhibit 2: Orthopaedic peer valuation			
Company	P/E 2015e	P/E 2016e	EV/Sales 2015e
aap Implantate*	66.7	29.7	1.90
Integra LifeSciences	21.3	19.3	2.87
OrthoFix	74.6	43.3	1.53
Smith & Nephew	20.5	18.1	3.59
Stryker	19.2	17.6	3.61
Tornier	N/A	N/A	3.97
Wright Medical	N/A	N/A	4.53
Zimmer	16.8	14.4	3.06
Average	36.5	23.7	3.13

Source: Bloomberg consensus at 25 June 2015 and \*Edison Investment Research

**Exhibit 3: DCF**

PV cash flows (€m)	6.4
PV intermediate term	39.7
PV residual	39.6
Enterprise value	85.8
Net debt/(cash)	(7.7)
Equity value	93.5
Shares in issue (m)	30.7
Share valuation (€)	3.05

Source: Company data and Edison Investment Research estimates

**Exhibit 4: Financial summary**

	€000s	2013	2014	2015e	2016e	2017e
		IFRS	IFRS	IFRS	IFRS	IFRS
December						
<b>PROFIT &amp; LOSS</b>						
Revenue		28,573	30,633	34,176	38,137	43,234
Total Output		29,611	32,846	36,731	40,706	45,819
Cost of Sales		(8,282)	(11,834)	(12,498)	(13,790)	(14,445)
Gross Profit		20,291	18,799	21,678	24,347	28,788
EBITDA		5,081	2,267	3,037	5,038	8,265
Operating Profit (before amort. and except.)		3,848	762	1,301	3,112	6,167
Intangible Amortisation		(3,129)	(816)	(2,182)	(2,263)	(2,345)
Exceptionals		0	0	0	0	0
Other		0	0	0	0	0
Operating Profit		719	(54)	(881)	849	3,822
Net Interest		(179)	(74)	(185)	(85)	134
Profit Before Tax (norm)		3,669	688	1,116	3,027	6,301
Profit Before Tax (FRS 3)		561	(177)	(1,066)	764	3,956
Tax		538	(361)	(405)	(560)	(800)
Profit After Tax (norm)		4,228	278	711	2,467	5,501
Profit After Tax (FRS 3)		1,099	(538)	(1,471)	204	3,156
Average Number of Shares Outstanding (m)		30.7	30.7	30.7	30.7	30.7
EPS - normalised (c)		13.79	0.91	2.32	8.04	17.94
EPS - normalised and fully diluted (c)		13.64	0.89	2.30	7.99	17.81
EPS - (IFRS) (c)		3.58	(1.75)	(4.80)	0.66	10.29
Dividend per share (p)		0.0	0.0	0.0	0.0	0.0
Gross Margin (%)		67.9	59.8	62.9	63.8	66.6
EBITDA Margin (%)		17.8	7.4	8.9	13.2	19.1
Operating Margin (before GW and except.) (%)		13.5	2.5	3.8	8.2	14.3
<b>BALANCE SHEET</b>						
Fixed Assets		22,394	25,017	27,272	28,582	29,661
Intangible Assets		14,502	15,198	15,088	14,892	14,610
Tangible Assets		5,906	7,690	10,055	11,561	12,921
Investments		1,986	2,129	2,129	2,129	2,129
Current Assets		42,843	32,840	29,866	29,579	32,608
Stocks		9,429	9,400	9,930	10,957	11,477
Debtors		6,866	8,838	9,860	10,480	11,289
Cash		1,580	12,165	7,639	5,705	7,405
Other		24,968	2,437	2,437	2,437	2,437
Current Liabilities		(13,671)	(7,452)	(7,954)	(8,524)	(9,224)
Creditors		(11,103)	(5,455)	(5,957)	(6,527)	(7,227)
Short term borrowings		(2,568)	(1,997)	(1,997)	(1,997)	(1,997)
Long Term Liabilities		(4,831)	(5,189)	(5,107)	(4,855)	(4,855)
Long term borrowings		(2,448)	(2,466)	(2,384)	(2,258)	(2,258)
Other long term liabilities		(2,383)	(2,723)	(2,723)	(2,597)	(2,597)
Net Assets		46,735	45,216	44,077	44,783	48,189
<b>CASH FLOW</b>						
Operating Cash Flow		3,383	(2,683)	2,076	4,022	7,677
Net Interest		(162)	(125)	(35)	64	284
Tax		326	(136)	(394)	(521)	(740)
Capex		(5,719)	(5,133)	(6,173)	(5,500)	(5,521)
Acquisitions/disposals		3,475	18,291	0	0	0
Financing		0	0	0	0	0
Dividends		0	0	0	0	0
Net Cash Flow		1,303	10,213	(4,526)	(1,934)	1,700
Opening net debt/(cash)		2,818	3,436	(7,702)	(3,258)	(1,450)
HP finance leases initiated		0	0	0	0	0
Other		(1,921)	925	82	126	0
Closing net debt/(cash)		3,436	(7,702)	(3,258)	(1,450)	(3,150)

Source: Company data and Edison Investment Research estimates

Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals work with leading companies, fund managers and investment banks worldwide to support their capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Conduct Authority ([www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584](http://www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584)). Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison and is not regulated by the Australian Securities and Investment Commission. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. [www.edisongroup.com](http://www.edisongroup.com)

#### DISCLAIMER

Copyright 2015 Edison Investment Research Limited. All rights reserved. This report has been commissioned by aap Implantate AG and prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Aus and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research. Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. FTSE International Limited ("FTSE") © FTSE 2015. "FTSE®" is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE's express written consent.